Evidence map›Paper›PMID 24770938›Full record

Trial reportStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2014

High-resolution analysis of DNA copy number alterations in rectal cancer: correlation with metastasis, survival, and mRNA expression.

Jérôme Doyen, Eric Letouzé, Laetitia Marisa, Aurélien de Reyniès, Gérard Milano, Marie-Christine Etienne-Grimaldi, Sylviane Olschwang, Jochen Gaedcke, Michael Ghadimi, Jean-Pierre Gérard

Abstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Multiple differential expression networks identify key genes in rectal cancer.Cancer biomarkers : section A of Disease markers · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Jérôme DoyenDepartment of Radiation Oncology, Centre Antoine-Lacassagne, 33 avenue de Valombrose, 06189, Nice, France, doyen@unice.fr.
Eric Letouzé
Laetitia Marisa
Aurélien de Reyniès
Gérard Milano
Marie-Christine Etienne-Grimaldi
Sylviane Olschwang
Jochen Gaedcke
Michael Ghadimi
Jean-Pierre Gérard
Centre Antoine Lacassagne · FRLa Ligue Contre le Cancer · FRUniversitätsmedizin Göttingen · DEInserm · FRUniversité Côte d'Azur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThis study aimed to determine the candidate genes and chromosomal imbalances capable of predicting occurrences of metastasis in patients with rectal cancer. PATIENTS AND

methodsFresh frozen tumor tissues from 80 patients with rectal cancer were prospectively collected and analyzed using Affymetrix HG-U133 Plus 2.0 gene expression arrays and high-resolution Illumina single-nucleotide polymorphism (SNP) arrays. Endpoints of the study were metastasis-free survival (MFS) and cancer-specific survival (CSS).

resultsThe median follow-up was 102 months (1-146). Deletions of 8p and 1p36-35 correlated with worse MFS (p = 0.005 and p = 0.01, respectively) and CSS (p = 0.001 and p = 0.01, respectively). Multivariate analysis identified 8p deletion as an independent prognostic factor for MFS (p = 0.04) and CSS (p = 0.003); 97 genes located on the 8p chromosome were significantly underexpressed in tumors with 8p deletion.

conclusionThis study shows for the first time in rectal cancer an independent correlation of 8p deletion with MFS and CSS and highlights potential new tumor suppressor genes.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overDNA Copy Number VariationsFemaleGenes, Tumor SuppressorGenetic MarkersGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationPrevalenceRectal NeoplasmsRisk FactorsGenetic MarkersRNA, Messenger

Identifiers

PMID24770938
OpenAlexW1259194687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.